Piper Sandler Upgrades Akebia Therapeutics to Overweight, Raises Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Christopher Raymond upgraded Akebia Therapeutics (NASDAQ:AKBA) from Neutral to Overweight and raised the price target from $2 to $4.
May 31, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics (NASDAQ:AKBA) has been upgraded from Neutral to Overweight by Piper Sandler, with a raised price target of $4.
The upgrade from Neutral to Overweight by Piper Sandler analyst Christopher Raymond indicates a positive outlook for Akebia Therapeutics. The raised price target from $2 to $4 suggests a potential upside for the stock, which may lead to a short-term increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100